SCHEMBL3762732

SCHEMBL3762732

CCc1cc(=O)oc2cc(O)ccc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B3 P37058 14/20 1.00
ALDH1A1 P00352 4/20 0.75
GAA P10253 3/20 0.75
ERAP1 Q9NZ08 1/20 0.75
AKR1B1 P15121 2/20 0.69
LCK P06239 1/20 0.69
FYN P06241 1/20 0.69
GRB2 P62993 1/20 0.69
KDM4E B2RXH2 3/20 0.67
GLA P06280 2/20 0.67
CA12 O43570 1/20 0.65
LMNA P02545 1/20 0.65
CYP1A2 P05177 1/20 0.65
CYP2C9 P11712 1/20 0.65
HPGD P15428 1/20 0.65
UGT1A1 P22309 1/20 0.65
MAOB P27338 1/20 0.65
CASP1 P29466 1/20 0.65
KDR P35968 1/20 0.65
CASP7 P55210 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL536846 0.89 HSD17B3 (1.00) HSD17B3ALDH1A1GAAERAP1AKR1B1
SCHEMBL24023252 0.86 HSD17B3 (0.76) HSD17B3ALDH1A1GAAERAP1AKR1B1
SCHEMBL4176874 0.86 HSD17B3 (0.76) HSD17B3ALDH1A1GAAERAP1AKR1B1
SCHEMBL10792047 0.86 HSD17B3 (0.76) HSD17B3ALDH1A1GAAERAP1AKR1B1
SCHEMBL5138108 0.85 HSD17B3 (1.00) HSD17B3ALDH1A1GAAERAP1AKR1B1
SCHEMBL10850530 0.85 HSD17B3 (0.72) HSD17B3ALDH1A1GAAERAP1AKR1B1
SCHEMBL205186 0.85 HSD17B3 (0.73) HSD17B3ALDH1A1GAAERAP1AKR1B1
SCHEMBL3868315 0.85 HSD17B3 (0.73) HSD17B3ALDH1A1GAAERAP1AKR1B1
SCHEMBL7738289 0.85 HSD17B3 (0.77) HSD17B3ALDH1A1GAAERAP1AKR1B1
SCHEMBL30185458 0.85 HSD17B3 (0.73) HSD17B3ALDH1A1GAAERAP1AKR1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022258005-A1 A PHOTORESPONSIVE DELIVERY SYSTEM BASED ON A MODIFIED PAMAM AND METHODS THEREOF THE UNIVERSITY OF HONG KONG (CN) 2022-12-15 WO disclosed
CN-110204535-B Coumarin hydrazine hydrate fluorescent probe and preparation method thereof 福州大学 2022-09-13 CN disclosed
US-10457619-B2 Resorcinol derivatives for cosmetic use thereof L'OREAL (FR) 2019-10-29 US disclosed
CN-110204535-A A kind of Coumarins hydrazine hydrate fluorescence probe and preparation method thereof 福州大学 2019-09-06 CN disclosed
EP-3039009-B1 MAO-B SELECTIVE INHIBITOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF AND USES THEREOF UNIV BRITISH COLUMBIA (CA) 2019-05-01 EP disclosed
US-9878046-B2 Adverse side-effects associated with administration of an anti-hyaluronan agent and methods for ameliorating or preventing the side-effects HALOZYME, INC. (US) 2018-01-30 US disclosed
WO-2017102536-A1 RESORCINOL DERIVATIVES FOR COSMETIC USE THEREOF L'OREAL (FR) 2017-06-22 WO disclosed
WO-2017102802-A1 RESORCINOL DERIVATIVES FOR THEIR COSMETIC USE L'OREAL (FR) 2017-06-22 WO disclosed
WO-2017102802-A1 RESORCINOL DERIVATIVES FOR THEIR COSMETIC USE L'OREAL (FR) 2017-06-22 WO disclosed
CN-106470977-A Water solublity can anakmetomeres probe, its synthetic intermediate and related detecting method 里昂高等师范学院 2017-03-01 CN disclosed
WO-1996039021-A1 FbLATE PROMOTER THE MONSANTO COMPANY (US) 1996-12-12 WO disclosed
CN-1027268-C Process for preparing benzopyrone-beta-D-thioxylosides FOURNIER IND & SANTE (FR) 1995-01-04 CN disclosed
EP-0421829-B1 Benzopyranone-beta-D-thioxylosides, method for their preparation and their use FOURNIER IND & SANTE (FR) 1994-11-09 EP disclosed
US-5169838-A Anticoagulants FOURNIER INDUSTRIE ET SANTE (FR) 1992-12-08 US disclosed
EP-0421829-A1 Benzopyranone-beta-D-thioxylosides, method for their preparation and their use FOURNIER INDUSTRIE ET SANTE (FR) 1991-04-10 EP disclosed
CN-1050544-A Novel benzopyrone-β-D-sulfo-xyloside, their preparation method and the application in treatment thereof FOURNIER IND & SANTE (FR) 1991-04-10 CN disclosed
EP-0111746-B1 SULFONIC-ACID ESTERS OF HYDROXYCOUMARINES, THEIR PREPARATION AND MEDICINES CONTAINING THEM BASF Aktiengesellschaft (DE) 1987-09-16 EP disclosed
US-4618622-A ANTIDEPRESSANTS, ANTIALLERGENS BASF AKTIENGESELLSCHAFT (DE) 1986-10-21 US disclosed
EP-0111746-A2 Sulfonic-acid esters of hydroxycoumarines, their preparation and medicines containing them BASF Aktiengesellschaft (DE) 1984-06-27 EP disclosed
US-4298614-A 5'-Aminoalkyl-4',4-dialkylpsoralens THOMAS C. ELDER, INC. (US) 1981-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10457619-B2 Resorcinol derivatives for cosmetic use thereof CBR3, C1S, TYR HSD17B3 185/4885ALDH1A1 476/4885GAA 1478/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.